A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety

Study Identifier:

405-201-00180

ClinicalTrials.gov Identifier:

NCT06973577

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

8446878522 or [email protected]

Recruiting

Subscribe to Updates

Study Details

Medical Condition

ADHD
Anxiety

Study Drug

Drug: Centanafadine

Date

Mar 2025 - Sep 2027

Phase 1/2

Phase 2/3

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults with Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety

Study Locations

Location

Status

Location

Clinical Research Site #017 - Harmonex Neuroscience Research

Dothan, Alabama, United States, 36303

Status

Recruiting

Location

Clinical Research Site #011 - NRC Research Institute

Orange, California, United States, 92868

Status

Recruiting

Location

Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc.

Jacksonville, Florida, United States, 32256

Status

Recruiting

Location

Clinical Research Site #006 - CNS Healthcare Orlando

Orlando, Florida, United States, 32801

Status

Recruiting

Location

Clinical Research Site #016 - Clinical Research of Southern Nevada, LLC

Las Vegas, Nevada, United States, 89128-0821

Status

Recruiting

Location

Clinical Research Site #021 - The Medical Research Network, LLC

New York, New York, United States, 10128

Status

Recruiting